Protagonist Therapeutics

PTGX stock is not Shariah-compliant

Powered by the Zoya API

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics is a biopharmaceutical company that discovers and develops peptide-based therapeutic drugs for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide for the treatment of polycythemia vera, hereditary hemochromatosis, and other blood disorders, PN-943 for inflammatory bowel disease, and PN-235 for IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, was incorporated in 2006, and is headquartered in Newark, California.

Frequently asked questions

Is Protagonist Therapeutics (PTGX) stock halal to invest in?
As of , PTGX is not Shariah-compliant and therefore considered halal to invest in. This assessment is based on the data available in Protagonist Therapeutics's most recent financial reports.
As of , PTGX is not Shariah-compliant and therefore not considered halal to invest in. This assessment is based on the data available in Protagonist Therapeutics's most recent financial reports.
As of , PTGX is flagged as not Shariah-compliant in terms of Shariah compliance based on the company's latest financial reports. This means that while the company's operations do not definitively violate Islamic guidelines, there are certain aspects of Protagonist Therapeutics's business that require careful consideration.
Does Protagonist Therapeutics have any interest income?
Yes, Protagonist Therapeutics does have interest income. According to the company's latest annual report for the fiscal year ending Dec 31, 2023, Protagonist Therapeutics reported revenue of 60000000 and interest income of 14898000. The interest income represents 19.89% of the combined total. It's worth noting that some companies may report additional interest income as part of their revenue. For a detailed breakdown of all interest income and revenue segments, please refer to the full Shariah compliance report available in the Zoya app.
No, Protagonist Therapeutics has not reported any interest income. According to the company's latest annual report for the fiscal year ending Dec 31, 2023, Protagonist Therapeutics reported total revenue of 60000000, with no separate interest income disclosed. However, it's worth noting that some companies may report interest income as part of their revenue. For a detailed breakdown of all interest income and revenue segments, please refer to the full Shariah compliance report available in the Zoya app.
What guidelines are used to determine if Protagonist Therapeutics stock is Shariah-compliant?
We use the guidelines set by the Accounting and Auditing Organization for Islamic Financial Institutions (AAOIFI) to assess Shariah compliance. AAOIFI is a leading international organization that establishes standards for Islamic finance. Their guidelines help determine if a company's business activities and financial structure align with Islamic principles. These standards are widely respected in the Islamic finance industry and provide a consistent framework for evaluating the Shariah compliance of stocks and other financial instruments. AAOIFI's Shariah board includes renowned scholars such as Sheikh Muhammad Taqi Usmani, Sheikh Mohamed Ali Elgari, Sheikh Abdullah AlManea, Sheikh Nizam Yaquby, and Dr. Aznan Hassan.
How often is Protagonist Therapeutics stock reviewed for Shariah compliance?
The Shariah compliance status of Protagonist Therapeutics stock is reviewed on a regular basis, with a minimum frequency of once per quarter. However, if there are any significant changes or major developments in the company's operations that may impact its compliance, an immediate review will be conducted to ensure ongoing adherence to Shariah principles.
How can I stay updated on Protagonist Therapeutics's compliance status?
To stay informed, we recommend regularly checking Zoya for updates. You can also enable alerts within the Zoya app to receive notifications whenever there is a change in the Shariah compliance of PTGX, or any other stocks you are monitoring. This is particularly useful as Shariah compliance can fluctuate due to changes in a company's financial ratios or business activities.
Are dividends from Protagonist Therapeutics stock considered halal?
Yes, dividends from PTGX are considered halal. However, you may need to purify a portion of the dividend if the company has any impermissible revenue. Shariah standards typically allow up to 5% of revenue from impermissible sources for a stock to remain compliant. To find the exact percentage of impermissible revenue for Protagonist Therapeutics (PTGX), check the Zoya app. For more details on the purification process, read our comprehensive guide.
No, dividends from PTGX are not considered halal because the stock is currently not Shariah-compliant. When a stock is non-compliant, any dividends received from it are considered impermissible income and should be donated to charity as a form of purification. To learn more about the purification process and how to handle impermissible income, read our comprehensive guide.
Do I need to pay Zakat on my Protagonist Therapeutics shares?
If you hold Protagonist Therapeutics stock as an investment, through an Employee Stock Ownership Plan (ESOP), stock options, restricted stock units (RSUs), or any other form of stock ownership, and meet the Nisab threshold, you may be required to pay Zakat on it. The calculation of Zakat on investments can be complex and depends on various factors. To help make this easy, we've created a free Zakat calculator for stocks. For a more seamless experience, use the Zoya mobile app, where you can link your brokerage account to automatically import holdings.

How to buy Protagonist Therapeutics (PTGX) stock on Zoya

  1. Sign up for a free Zoya account
    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Zoya app for iOS or Android.
  2. Link a brokerage account
    Zoya partners with leading brokerages like Alpaca and others for a seamless way to buy and manage stocks through Zoya.
  3. Decide how much to invest
    Navigate to the search screen and type the name of the stock into the search bar. Then, click the buy button and input the amount you'd like to invest, either in terms of dollars or number of shares. Review the real-time stock price and estimated quantity of shares before confirming your investment.
  4. Manage your portfolio in one place
    You can find your newly purchased stock in your Zoya portfolio alongside the rest of your holdings. Enable alerts to get notified of any changes in your portfolio's Shariah compliance.

Community posts

Related stocks

See how Protagonist Therapeutics compares with its peers: